Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. [electronic resource]
Producer: 20080522Description: 228-36 p. digitalISSN:- 1556-1380
- Adult
- Aged
- Aged, 80 and over
- Alkaline Phosphatase -- blood
- Biomarkers, Tumor -- urine
- Bone Density Conservation Agents -- administration & dosage
- Bone Neoplasms -- blood
- Canada -- epidemiology
- Carcinoma, Non-Small-Cell Lung -- metabolism
- Collagen Type I -- drug effects
- Diphosphonates -- administration & dosage
- Enzyme-Linked Immunosorbent Assay
- Female
- Follow-Up Studies
- Humans
- Imidazoles -- administration & dosage
- Lung Neoplasms -- metabolism
- Male
- Middle Aged
- Osteoclasts -- metabolism
- Peptides -- drug effects
- Retrospective Studies
- Time Factors
- Treatment Outcome
- United States -- epidemiology
- Zoledronic Acid
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.